The speed of developing diagnostics for SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19), has been quite remarkable. Diagnostics have focused on nucleic acid amplification testing (NAAT) to identify infected individuals in acute-phase disease for timely implementation of mitiga...tion strategies and case management. More and more immunodiagnostics, mostly rapid diagnostic tests, are being made available as an alternative to NAATs. This type of test can be used out-of-laboratory conditions at large scale.
more
خيارات المرافق الخاصة
بغسل اليدين للإعدادات
محدودة الموارد
This document provides guidance to AU Member States, states/local bodies, and communities
on how to construct and maintain non-contact hand washing stations like Tippy Taps and other
al...ternative hand washing stations.
more
ل المتلازمة التنفسية الحادة ٢خطر انتقال فيروس كورونا المستجدعلى مدى الأسابيع الماضية، كان هناك اهتمام واسع من جانب وسائل الإعلام حو [فيروس السارس ) من قبل الأفراد ع...ديمي الأعراض. وقد نوقشت هذه الحالة SARS-CoV2الوخيمة (ا على نطاق واسع على منصات مختلفة على مستوى العالم. الغرض من بيان ًأيضAfricaهذا الموقف هو أن تقوم المراكز الأفريقية لمكافحة الأمراض و الوقاية منها ( المتلازمة التنفسية الحادة الوخيمة ٢) بتوضيح حالة انتقال فيروس السارس CDCالأعراض.] عن طريق الأفراد ما قبل الإصابة بالأعراض والأفراد عديميSARS-CoV2[
more
إن حول الإصدارات الإعلامية للنتائج الأولية للتجربة الإكلينيكية العشوائية ٍّتام) والتي تضمنت ديكساميثازون على إدراك Africa CDC المركز الأفريقي لمكافحة الأمراض و الوقاي...ة منها، UKالكبيرة التي أجريت في المملكة المتحدة () أفاد الباحثون بأن إعطاء ديكساميثازون ۱وكورتيكوستيرويد كإحدى أذرع العلاج.(عن طريق الفم أو عن طريق الحقن أدى إلى انخفاض حوالي ثلث الوفيات بين الذين يحتاجون إلى i]COVID-19المرضى المصابين بفيروس كورونا المستجد [َّتهوية ميكانيكية وحوالي الخمس للمرضى الذين يحتاجون إلى الأكسجين. إنا مدرج في قائمة الأدوية الأساسية ًديكساميثازون هو دواء عام وغير مكلف نسبيإفريقيا.لمنظمة الصحة العالمية ويستخدم على نطاق واسع في
more
الاستراتيجيات لإدارة النقص الحاد في معدات الحماية الشخصية خلال جائحة فيروس COVID-19
This guidance provides considerations and a series of options that can be used to inform country strategies in managing any shortages of personal prote...ctive equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WHO and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
إرشاداتٌ حول إنشاء عنابر العزل الخاصة بالحالات المصابة بفيروس كورونا المستجد
This document simplifies the WHO guidance on severe acute respiratory infection (SARI) treatment centres and is meant to be accessible to healthcare work...ers, policymakers and others who want
a quick overview of the key requirements for a COVID-19 isolation centre either within an existing facility or as a standalone centre.
more
تطوير لقاح مرض فيروس كورونا ] واستراتيجية المستجد [COVID-19
In an effort to limit transmission and achieve pandemic control on the continent, Africa CDC is proposing the following measures to be taken by all Member States:
Remain vigilant
Countries should adapt or adopt best practices, strategies, guidelines and recommendations proposed by the Africa CDC... and World Health Organization (WHO), aimed at limiting transmission. Measures taken should strike a balance between saving lives and minimizing the impact of the pandemic on the economy and social wellbeing of citizens.
more
AMSP opens COVID-19 vaccines pre-orders for 55 African Union Member States
This guidance covers diagnosis and care of patients with long-term effects of COVID-19. It makes recommendations for the care of adults and children who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It is meant for health and care practitioners. This interim documen...t has been developed by the Africa Taskforce on Coronavirus Case Management Technical Working Group and will be continuously reviewed and updated in response to emerging evidence
more
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
Key findings from a February 2021 survey from the Partnership for Evidence-Based Response to COVID-19 (PERC)
This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.
In 2007, WHO warned that infectious diseases are emerging and re-emerging at a rate that has not been seen before. The potential for infectious diseases to spread rapidly results in high morbidity and mortality, causing a potential global public health treat of major concern.
Several factors are ...contributing to the (re)emergence of infectious diseases such as population growth, living in close contact with animals, frequent travelling, poverty, destructive ecological changes due to economic development and land use and climate change result in global warming.
Especially Africa is at a threat for (re)emerging infectious diseases due to the huge population growth (expected to reach 2.5 billion by 2050) with rapid urbanisation. Additionally, people across and beyond the continent are excessively mobile which is combined with a weak health system. Moreover, the risk of (re)emerging infectious disease is further heightened by three newly adopted continental initiatives: African Continental Free Trade Area, Free Movement of Persons and African Passport and Single African Air Transport Market.
more